Chugai Pharmaceutical : Notice of Revisions to Dividend Forecast for Fiscal Year Ending December 31, 2021
October 22, 2021 at 04:14 am EDT
Share
October 22, 2021
Name of listed company: Chugai Pharmaceutical Co., Ltd.
Code number:
4519 (1st Section of Tokyo Stock Exchange)
Head office:
1-1,Nihonbashi-Muromachi2-Chome,Chuo-ku, Tokyo
President & CEO:
Osamu Okuda
Inquiries to:
Toshiya Sasai
Head of Corporate Communications Dept.
Tel: +81-(0)3-3273-0554
Notice of Revisions to Dividend Forecast for Fiscal Year
Ending December 31, 2021
Chugai Pharmaceutical Co., Ltd.announced that the Company resolved at the meeting of its Board of Directors held on October 22, 2021 to revise the dividend forecast per share as described below.
1. Reasons for the revision
Reflecting the significant changes in the business environment, year-end dividend forecast has been revised to undecided. The year-end dividends will be decided after the fiscal year end based on basic profit distribution principles*.
*Regarding income distribution, taking into account the strategic funding needs and earning prospects, Chugai aims for a consolidated dividend payout ratio of 45% on average in comparison with Core EPS to provide a stable allocation of profit to all shareholders.
2. Contents of the revision
Annual dividends per share (JPY)
End of second
End of FY
Total
quarter
Previous forecast
JPY 30.00
JPY 60.00
Revised forecast
Undecided
Undecided
Results for FY ending Dec. 2021
JPY 30.00
Results for FY ending Dec. 2020 **
JPY 25.00
JPY 30.00
JPY 55.00
Effective July 1, 2020, Chugai implemented a three-for-one stock split of its common stock. The dividends are calculated based on the assumption that the stock split was implemented at the beginning of the fiscal year 2020.
###
Attachments
Original document
Permalink
Disclaimer
Chugai Pharmaceutical Co. Ltd. published this content on 22 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 October 2021 08:13:13 UTC.
Chugai Pharmaceutical Co. Ltd specializes in the research, development, manufacturing and marketing of drugs especially for cancers (40.8% of net sales), bones and joints diseases treatment (18.4%), and kidney diseases (5.9%).
Net sales are distributed geographically as follows: Japan (74,3%), Switzerland (22,8%) and other (2,9%).